Articles related to GUIDELINES/RECOMMENDATIONS

Beyond the strong recommendation for bisphosponates as initial medical therapy in postmenopausal women with osteoporosis, the updated guidelines also suggest (not recommend) denosumab as second line therapy in women, bisphosphonates for osteoporosis in men, and romosozumab in women with very high risk of fractures. For the complete updated guideline, see Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.

The updated ADA standards have several significant changes. These include: A revised definition of HTN to match that of the ACC and AHA New recommendations for statin use Changes to recommendations around CKD treatment Revised weight loss goals Use of diabetes technology And much more

The updated AAP guidance “recommends programmatic consideration of providing more than 5 consecutive doses of palivizumab depending on the duration of the current RSV surge in a given region of the country.”

The controversial 2016 CDC opioid guideline for chronic pain is updated and replaced by the new guidance, which addresses acute, subacute, and chronic pain for primary care and other clinicians. Some organizations misapplied the 2016 guideline, which was perceived as imposing strict opioid dose and duration limits. As a result, the guideline authors clarified their recommendations in 2019.

The new guidelines have drawn criticism and many or most hospitals are sticking to state guidelines, which generally mandate masking. Megan Ranney, MD, MPH, of Brown University tweeted that CDC’s logic “escapes me,” as it pertains to society’s “most health-vulnerable” people in a setting with a higher-than-average risk of COVID positivity.

Patients discontinuing antidepressant therapy experience insomnia, flu-like symptoms, mood disturbances, dizziness, and paresthesias — among a broad array of adverse effects. Those symptoms can last for days to months. This narrative review describes the array of discontinuation symptoms and their causes and provides practical clinical guidance for discontinuing antidepressants to minimize the risk of antidepressant discontinuation syndrome (ADS).